REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo offers hope for hard-to-treat lymphoma patients before transplant
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that has returned or not responded to standard therapy. First, patients receive tafasitamab and lenalidomide, then a chemotherapy combo called ICE. The goal is to shrink or eliminate cancer before a stem …
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 26, 2026 07:42 UTC
-
New drug combo aims to outsmart tough lymphoma
Disease control Recruiting nowThis study is for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It tests a combination of two drugs: epcoritamab, which helps the immune system attack cancer cells, and ibrutinib, which blocks signals that help cance…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated May 26, 2026 07:34 UTC
-
New hope for Hard-to-Treat lymphoma: experimental drug tegavivint enters human testing
Disease control Recruiting nowThis early-stage trial is testing a drug called tegavivint in about 18 adults whose large B-cell lymphoma has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Tegavivint works by blocking certain protein…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated May 26, 2026 07:22 UTC
-
New 5-Drug cocktail ViPOR targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve co…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC